The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Market Size Is Forecasted For The Hyqvia Market By 2030 Based On Its 2026 Value?
Historical expansion stemmed from the constraints of intravenous immunoglobulin therapy, the elevated susceptibility to infection among primary immunodeficiency patients, the prompt uptake of subcutaneous immunoglobulins, the imperative for enhanced well-being, and the increasing development within immunology specialty services.
The market’s expansion throughout the projected period is driven by several factors, including an increase in primary immunodeficiency diagnoses, the growth of home healthcare services, enhanced management of pediatric PI, a preference for longer intervals between doses, and the expansion of specialty pharmacy distribution. Significant trends anticipated during this forecast period involve a shift towards less frequent immunoglobulin infusions, a growing embrace of home-based infusion treatments, an increasing demand for combined immunotherapy products, greater patient convenience in PI treatment, and an expanded adoption of subcutaneous immunoglobulin.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20092&type=smp
What Market Drivers Are Helping Shape The Hyqvia Market Expansion?
The expanding occurrence of autoimmune diseases is projected to stimulate the growth of the hyqvia market moving forward. Autoimmune diseases are conditions where the immune system mistakenly targets healthy cells, tissues, or organs, resulting in inflammation and dysfunction. The increase in autoimmune diseases is attributed to a combination of factors, including genetic predispositions, environmental triggers, dietary shifts, greater exposure to pollutants, and enhanced diagnostic capabilities. Hyqvia serves in treating autoimmune diseases by providing immunoglobulin therapy, which helps regulate the immune system and mitigate abnormal immune responses that attack the body’s own tissues. For instance, in May 2023, according to the NIHR Imperial Biomedical Research Centre, a UK-based government research institute and agency, a study examining anonymized electronic health records from 22 million UK individuals identified 19 common autoimmune diseases, affecting approximately 10% of the population, specifically 13% of women and 7% of men. Consequently, the rising prevalence of autoimmune diseases is driving the growth of the hyqvia market.
How Is The Hyqvia Market Examined Through Segment Analysis?
The hyqvia market covered in this report is segmented –
1) By Patient Demographics: Pediatric Patients, Adult Patients
2) By Distribution Channel: Hospitals, Specialty Pharmacies, Home Healthcare Providers, Retail Pharmacies
3) By Application: Primary Immunodeficiency, Chronic Inflammatory Demyelinating Polyneuropathy, Other Applications
Which Trends Are Supporting The Evolution Of The Hyqvia Market?
A key emphasis in the hyqvia market is on developing innovative products, such as immune globulin infusion, for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) and primary immunodeficiency (PI). Immune globulin infusion is a medical procedure that involves delivering antibody-rich plasma proteins to manage immune deficiencies and autoimmune disorders. For example, in January 2024, Takeda Pharmaceutical Company Ltd., a Japan-based pharmaceutical company, announced the U.S. Food and Drug Administration (FDA) had approved its product, HYQVIA® (immune globulin infusion 10% [human] with recombinant human hyaluronidase), as a maintenance therapy for adults diagnosed with chronic inflammatory demyelinating polyneuropathy (CIDP). This FDA approval allows HYQVIA to be used to prevent relapses of neuromuscular disability and impairment associated with CIDP, a rare neuromuscular disorder that affects approximately five to seven individuals per 100,000 in the U.S.
Which Companies Form The Competitive Landscape Of The Hyqvia Market?
Major companies operating in the hyqvia market are Takeda Pharmaceutical Company Limited
Access The Complete Hyqvia Market Report:
https://www.thebusinessresearchcompany.com/report/hyqvia-global-market-report
Which Region Contributes The Most To The Hyqvia Market?
North America was the largest region in the hyqvia market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the hyqvia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model